Floatz logo

ze 50-0134

CLL (Chronic Lymphocytic Leukemia)

Lomond Therapeutics Holdings, Inc.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the CLL (Chronic Lymphocytic Leukemia) cohort.

Asset / SponsorPhaseRating
Ruxolitinib
Center for International Blood and Marrow Transplant Research
Phase 3BB
TACROLIMUS
Center for International Blood and Marrow Transplant Research
Phase 2B
Palifermin
Center for International Blood and Marrow Transplant Research
Phase 2CCC
ABATACEPT RECOMBINANT
Center for International Blood and Marrow Transplant Research
Phase 2CCC
Ptcy
Center for International Blood and Marrow Transplant Research
Phase 2CCC

View all 11 →

Same molecule, other indications

ze 50-0134 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →